Neoplasms – Page 10

Bayer and NextRNA Therapeutics Collaborate on $547 Million Deal to Develop Innovative Cancer Therapies Targeting Long Non-Coding RNAs

1 year ago talkbio0Tagged Bayer, Drug Development, Long Intergenic Non-Protein Coding RNA, Neoplasms, NextRNA, Partnership

Bayer, NextRNA Therapeutics, lncRNA, small molecules, cancer, oncology, partnership, drug development

FDA Approves Illumina’s TruSight Oncology Comprehensive Test for Pan-Cancer Companion Diagnostics

1 year ago talkbio0Tagged Approved, cellular targeting, Comprehensive, Diagnostics, Gene Fusion, Illumina, Neoplasms, NTRK, pan-cancer, Pet Animal, Precision - temporal, RET protein, human, TruSight Oncology, United States Food and Drug Administration

FDA approval, Illumina, TruSight Oncology Comprehensive, pan-cancer, companion diagnostics, NTRK gene fusions, RET fusion-positive NSCLC, targeted therapies, precision oncology.

Merck & Co., Daiichi Sankyo Strengthen Partnership with New DLL3 Cancer Drug Agreement

1 year ago talkbio0Tagged Antibody-Drug, Daiichi, DLL3, DLL3 gene, Immunostimulating conjugate (antigen), Merck & Co., MK-6070, Neoplasms, Neurosecretory Systems, Oncology Pipeline, Sankyo, Small cell carcinoma of lung, T-Lymphocyte

Merck & Co., Daiichi Sankyo, DLL3, T-cell engager, MK-6070, small cell lung cancer, neuroendocrine tumors, antibody-drug conjugates, oncology pipeline

Eisai Partners with SEED Therapeutics for $1.5 Billion Biobucks Deal in Neurodegeneration and Oncology

1 year ago talkbio0Tagged biobucks, Eisai, molecular glue degraders, Neoplasms, Nerve Degeneration

Eisai, SEED Therapeutics, biobucks deal, neurodegeneration, oncology, molecular glue degraders

Impact of Padcev/Keytruda Momentum on US Sales of Merck KGaA’s Bavencio in Bladder Cancer

1 year ago talkbio0Tagged Bavencio, Keytruda, Malignant neoplasm of urinary bladder, Merck KGaA, Neoplasms, Padcev, Sales - occupational activity

Merck KGaA, Bavencio, Padcev, Keytruda, bladder cancer, US sales, pharmaceuticals, oncology

FibroGen Lays Off 75% of US Staff After Cancer Drug Fails in Two Phase III Trials

1 year ago talkbio0Tagged Anemia, Antineoplastic Agents, Astellas, AstraZeneca, FibroGen, Neoplasms, pamrevlumab, Pancreatic carcinoma, Pharmacotherapy, Phase 3 Clinical Trials, roxadustat

FibroGen, cancer drug, layoffs, Phase III trials, pamrevlumab, oncology, pancreatic cancer, chemotherapy, anaemia therapy, roxadustat, Astellas, AstraZeneca

Merck & Co.’s Keytruda Achieves $7 Billion in Quarterly Sales, Surpassing Expectations

1 year ago talkbio0Tagged Keytruda, Merck & Co., Neoplasms, quarterly sales, Winrevair

Merck & Co., Keytruda, quarterly sales, Winrevair, pharmaceuticals, oncology

AstraZeneca Acquires Pinetree’s EGFR Degrader for $45 Million Upfront

1 year ago talkbio0Tagged AstraZeneca, Cancer Therapeutic Procedure, Epidermal Growth Factor Receptor, licensing agreement, milestone payments, molecular glues, Neoplasms, Pinetree, Protein Degradation, Metabolic, protein degrader, royalties

AstraZeneca, Pinetree Therapeutics, EGFR degrader, protein degrader, oncology, licensing agreement, milestone payments, royalties, targeted protein degradation, molecular glues, cancer treatment